Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

Share Price is delayed by 15 minutes
Get Live Data
12.75    0.50 (4.08%)
Bid:
12.50
Ask:
13.00
Spread: 0.50 (4.00%)
Market Cap: £32.01m
ABDX Live PriceLast checked at - London Stock Exchange

Intraday Abingdon Healt. Share Chart

Result of AGM

19 Nov 2024 12:00

RNS Number : 8264M
Abingdon Health PLC
19 November 2024
 

 

 

19 November 2024

 

Abingdon Health Plc

("Abingdon" or the "Company")

 

Result of Annual General Meeting

 

Abingdon Health plc (AIM:ABDX), a leading international lateral flow contract development and manufacturing organisation, is pleased to announce that at the Annual General Meeting held earlier today, all resolutions were duly passed with greater than 99.8% of votes in favour.

 

Enquiries

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Chris Hand, Executive Chairman

Zeus (Sole Broker and Nominated Adviser)

Tel: +44 (0) 20 3829 5000

Chris Fielding / Alexandra Campbell-Harris (Corporate Finance)

Fraser Marshall (Corporate Broking)

Walbrook PR (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

Phillip Marriage

+44 (0)7867 984 082

 

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.

 

The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKCBPDBDDKDD
Date   Source Headline
17th Dec 20247:00 amRNSContract win: sexually transmitted disease tests
19th Nov 202412:00 pmRNSResult of AGM
19th Nov 20247:00 amRNSAGM Statement
21st Oct 20244:00 pmRNSNotice of AGM
15th Oct 20247:00 amRNSOpening of US commercial office and laboratory
8th Oct 20247:00 amRNSFinal Results
4th Oct 20247:00 amRNSNotice of Results
29th Aug 20247:00 amRNSResults of the Retail Offer
27th Aug 20249:26 amRNSTR - 1
20th Aug 20243:44 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:45 pmRNSTR-1
19th Aug 20249:00 amRNSRetail Offer Launch
15th Aug 20243:50 pmRNSCompletion of Acquisition of Compliance Solutions
12th Aug 202410:41 amRNSResult of General Meeting and Total Voting Rights
25th Jul 202411:52 amRNSResult of Placing
24th Jul 20244:51 pmRNSProposed Acquisition and Placing Notice of GM
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
9th Jul 20247:00 amRNSTrading Update
31st May 20247:00 amRNSTotal Voting Rights – 31 May 2024
15th May 20247:00 amRNSLaunch of the Saliva Pregnancy self-test in Boots
8th May 20247:00 amRNSChange of Nominated Adviser and Sole Broker
7th May 20247:00 amRNSAcquisition of IVDeology Holdings Limited
25th Mar 20247:00 amRNSDesign freeze completion & strategic partnership
20th Mar 20247:00 amRNSLaunch of OEM self-tests in Boots
15th Mar 20241:00 pmRNSCEO Interview
14th Mar 20247:00 amRNSInterim Results
11th Mar 20248:53 amRNSNotice of Results
11th Jan 20247:01 amRNSUpdate to Shareholder Concert Parties
11th Jan 20247:00 amRNSTrading Update
15th Dec 202310:15 amRNSResult of AGM
15th Dec 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
25th Oct 20237:00 amRNSDirector/PDMR Shareholding
24th Oct 20237:01 amRNSAward of Options under LTIP
24th Oct 20237:00 amRNSAppointment of Interim Finance Director
18th Oct 20237:00 amRNSDirectorate Change
17th Oct 20237:00 amRNSFinal Results
11th Oct 20237:00 amRNSNotice of Results
7th Sep 20237:00 amRNSPartnership with Morrama
30th Aug 20237:00 amRNSAgreed changes to Concert Party
15th Aug 20237:00 amRNSSalistick™ to be launched in Tesco
6th Jul 20237:00 amRNSTrading Update
19th Jun 20237:00 amRNSLaunch of Salistick™ saliva pregnancy test
31st Mar 20237:00 amRNSInterim Results
24th Mar 202312:30 pmRNSNotice of Results
20th Mar 20237:00 amRNSSenzo & Abingdon enter into strategic partnership
7th Mar 20237:00 amRNSAppDx® granted further patent
1st Mar 20237:00 amRNSDirector Share Transfer to Trust

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.